LN 144

Drug Profile

LN 144

Alternative Names: Autologous T-cell therapy - Iovance Biotherapeutics; Contego; LN144; TILs - Iovance Biotherapeutics; Tumour infiltrating lymphocytes - Iovance Biotherapeutics

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Iovance Biotherapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 13 Dec 2017 Updated efficacy and adverse events data from a phase II trial in Malignant melanoma released by Iovance Biotherapeutics
  • 09 Nov 2017 Interim efficacy data from a phase II trial in Malignant melanoma released by Iovance Biotherapeutics
  • 31 Oct 2017 Iovance Biotherapeutics receives approval for clinical trial applications for initiation of a phase II trial for Malignant melanoma (Metastatic disease) in Hungary and the United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top